Assad Mouhaffel, MD
Cardiovascular Disease · West Monroe, LANPI 1760591010
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,900 of the $7,968 with a category attached, or 86.6%. It is spread thinly across 39 manufacturers, the largest accounting for just 14.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,715 and has fallen 62.4% since, to $645 in 2025.
Across 381 payments — averaging $20.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$1K
- Novartis$1K
- Johnson & Johnson$1K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$962
- Amgen$404
- E.r. Squibb & Sons, L.L.C.$365
- plus $3K from 33 others
Across 389 payments — averaging $3703.31 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$464K
- Novartis$288K
- Janssen Research & Development, LLC$150K
- Esperion Therapeutics, Inc.$148K
- AstraZeneca$118K
- Vertex$83K
- plus $189K from 11 others
What the payments were for
- Travel & lodging$1,04013%
- Food & beverage$6,90087%
- Education$280%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 7 | $1,123 |
| Novartis | 81 | $1,085 |
| Johnson & Johnson | 49 | $1,028 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 57 | $962 |
| Amgen | 20 | $404 |
| E.r. Squibb & Sons, L.L.C. | 29 | $365 |
| Medtronic | 9 | $303 |
| Merck | 14 | $263 |
| AstraZeneca | 12 | $181 |
| Inari Medical, Inc. | 4 | $176 |
| Kowa Pharmaceuticals America, Inc. | 9 | $167 |
| Irhythm Technologies, Inc. | 7 | $165 |
| Scpharmaceuticals Inc. | 8 | $147 |
| Penumbra, Inc. | 2 | $143 |
| Sanofi-aventis U.S. LLC | 7 | $134 |
| Pfizer | 8 | $130 |
| Gilead | 9 | $115 |
| Philips North America LLC | 6 | $94 |
| Kestra Medical Technology Services, Inc. | 4 | $94 |
| Cvrx, Inc. | 1 | $78 |
| Bayer | 4 | $73 |
| Boston Scientific | 4 | $73 |
| Esperion Therapeutics, Inc. | 5 | $72 |
| Boehringer Ingelheim | 4 | $69 |
| Lexicon Pharmaceuticals, Inc. | 4 | $67 |
| Arineta, Inc | 1 | $65 |
| GE HealthCare | 1 | $64 |
| Inspire Medical Systems, Inc. | 1 | $63 |
| Abiomed | 2 | $49 |
| Amarin Pharma, Inc. | 2 | $36 |
| Itamar Medical Inc | 1 | $33 |
| United Therapeutics Corporation | 1 | $24 |
| Alnylam Pharmaceuticals Inc. | 1 | $23 |
| Novo Nordisk | 1 | $22 |
| Cardiovascular Systems Inc. | 2 | $21 |
| AbbVie | 1 | $15 |
| Edwards Lifesciences | 1 | $14 |
| Athena Bioscience, LLC | 1 | $13 |
| Biocompatibles, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AVEIR$975
- IN.PACT Admiral$147
- Indigo System$125
- XARELTO$120
- FLOWTRIEVER CATHETER, S$109
- CT THROMBECTOMY SYSTEM KIT$109
How this compares
$7,968 in reported general payments places this provider in the 70th percentile of 281 cardiovascular disease providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,156 | $934,332 |
| EntrestoSacubitril/Valsartan | 496 | $426,628 |
| Repatha SureclickEvolocumab | 203 | $138,548 |
| XareltoRivaroxaban | 195 | $137,984 |
| OpsumitMacitentan | 11 | $135,410 |
| MultaqDronedarone Hcl | 83 | $82,910 |
| Ambrisentan | 16 | $45,357 |
| FarxigaDapagliflozin Propanediol | 50 | $39,617 |
| JardianceEmpagliflozin | 35 | $32,538 |
| Ranolazine ErRanolazine | 317 | $20,672 |
| Isosorbide Dinitrate | 492 | $19,689 |
| Metoprolol Succinate | 1,342 | $17,156 |
| Amiodarone Hcl | 688 | $16,157 |
| Atorvastatin Calcium | 1,213 | $12,511 |
| MounjaroTirzepatide | 12 | $12,013 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $130 | $934,3321,156 claims |
| NovartisEntresto | $1,085 | $426,628496 claims |
| Johnson & JohnsonXarelto | $1,028 | $137,984195 claims |
| Sanofi-aventis U.S. LLCMultaq | $134 | $82,91083 claims |
| AstraZenecaFarxiga, Brilinta | $181 | $48,61467 claims |
| Boehringer IngelheimJardiance | $69 | $32,53835 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 281 cardiovascular disease providers in Louisiana.
Other cardiovascular disease in West Monroe
- Keith FerdinandNew Orleans$239K
- Carl LavieNew Orleans$228K
- Imran ChaudryMonroe$202K
- Corey FosterLake Charles$158K
- George KaramBaton Rouge$110K
- Harry HawthorneAlexandria$89K
- Mazen IqbalMonroe$82K
- Darrell SoletMorgan City$81K
- Ghiath MikdadiHammond$76K
- Samuel StaggHouma$70K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.